Osetron (Ondansetron Hydrochloride)

Ondansetron, the active ingredient in Osetron, is a 5‑HT3 receptor antagonist presented as a [strength]/[form] for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative settings in adult patients.

GNH USA supplies Osetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Osetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical contexts.

Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of episodes in patients receiving cytotoxic agents. Radiation‑induced nausea and vomiting: helps manage symptoms during and after radiotherapy. Postoperative nausea and vomiting: provides prophylaxis and treatment after surgical procedures.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhoea - Abdominal discomfort

Serious or Rare Side Effects: - QT interval prolongation and cardiac arrhythmias - Severe allergic reactions such as anaphylaxis - Serotonin syndrome when combined with other serotonergic agents - Severe skin reactions, including Stevens‑Johnson syndrome

Before prescribing Osetron, clinicians should consider several safety factors.

Assess cardiac history: evaluate risk of QT prolongation. Monitor electrolytes: correct hypokalaemia or hypomagnesaemia. Use caution in hepatic impairment: dose adjustment may be required. Avoid concomitant use with other QT‑prolonging drugs when possible. Store at room temperature: keep in the original packaging, protect from moisture.

Ondansetron may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Apomorphine: can cause severe hypotension. - Carbamazepine: induces metabolism, reducing ondansetron efficacy. - Ritonavir: inhibits metabolism, increasing drug levels.

Moderate Interactions (Monitor Closely): - Atypical antipsychotics (e.g., olanzapine): may enhance QT effects. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): increase risk of serotonin syndrome. - Antifungal agents (e.g., fluconazole): may raise plasma concentrations.